Results 51 to 60 of about 343,599 (390)
Therapeutic Potential of Secreted Amyloid Precursor Protein APPsα
Frontiers in Molecular Neuroscience, 2017 Cleavage of the amyloid precursor protein (APP) by α-secretase generates an extracellularly released fragment termed secreted APP-alpha (APPsα). Not only is this process of interest due to the cleavage of APP within the amyloid-beta sequence, but APPsα ...
B. Mockett +3 more
semanticscholar +1 more source
Journal of Pharmacological Sciences, 2012 Neuregulin-1 (NRG1) plays important roles in the development and plasticity of the brain, and it is also reported to have potent neuroprotective properties.
Junghwa Ryu +6 more
doaj +1 more source
Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in alzheimer’s disease and parkinson’s disease [PDF]
, 2017 Alzheimer's disease and Parkinson's disease are two common neurodegenerative diseases of the elderly people that have devastating effects in terms of morbidity and mortality.
Chakrabarti, S. +3 more
core +3 more sources
Amyloid Precursor-like Protein 1 Influences Endocytosis and Proteolytic Processing of the Amyloid Precursor Protein [PDF]
Journal of Biological Chemistry, 2006 Ectodomain shedding of the amyloid precursor protein (APP) is a key regulatory step in the generation of the Alzheimer disease amyloid beta peptide (Abeta). The molecular mechanisms underlying the control of APP shedding remain little understood but are in part dependent on the low density lipoprotein receptor-related protein (LRP), which is involved ...
Neumann, Stephanie +6 more
openaire +3 more sources
Bangladesh Journal of Pharmacology, 2016 The aim of this study was to assess the potential of amyloid precursor protein in peripheral granulocytes as a diagnostic biomarker for early detection of Alzheimer’s disease.
Xiaonan Wang +4 more
doaj +2 more sources
Cytoprotective functions of amyloid precursor protein family members in stress signaling and aging [PDF]
, 2013 Poster presentation: Molecular Neurodegeneration: Basic biology and disease pathways Cannes, France. 10-12 September 2013. Background: The amyloid precursor protein (APP) is processed via two different metabolic pathways: the amyloidogenic and the non ...
Chang, Steffi +4 more
core +1 more source
Neural Regeneration Research, 2016 Rosiglitazone up-regulates caveolin-1 levels and has neuroprotective effects in both chronic and acute brain injury. Therefore, we postulated that rosiglitazone may ameliorate diffuse axonal injury via its ability to up-regulate caveolin-1, inhibit ...
Yong-lin Zhao +5 more
doaj +1 more source
Scientific Reports, 2021 Individuals who have Down syndrome (caused by trisomy of chromosome 21), have a greatly elevated risk of early-onset Alzheimer’s disease, in which amyloid-β accumulates in the brain. Amyloid-β is a product of the chromosome 21 gene APP (amyloid precursor
Justin L. Tosh +12 more
doaj +1 more source
Traumatic Microhemorrhages Are Not Synonymous With Axonal Injury
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Diffuse axonal injury (DAI) is caused by acceleration‐deceleration forces during trauma that shear white matter tracts. Susceptibility‐weighted MRI (SWI) identifies microbleeds that are considered the radiologic hallmark of DAI and are used in clinical prognostication.
Karinn Sytsma +9 more
wiley +1 more source
Amyloid-β acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2. [PDF]
, 2012 BACKGROUND: It is becoming increasingly evident that deficits in the cortex and hippocampus at early stages of dementia in Alzheimer's disease (AD) are associated with synaptic damage caused by oligomers of the toxic amyloid-β peptide (Aβ42).
Alifragis, P +5 more
core +2 more sources